IBDEI10P ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16362,1,4,0)
 ;;=4^R80.9
 ;;^UTILITY(U,$J,358.3,16362,2)
 ;;=^5019599
 ;;^UTILITY(U,$J,358.3,16363,0)
 ;;=Z87.442^^88^876^84
 ;;^UTILITY(U,$J,358.3,16363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16363,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
 ;;^UTILITY(U,$J,358.3,16363,1,4,0)
 ;;=4^Z87.442
 ;;^UTILITY(U,$J,358.3,16363,2)
 ;;=^5063497
 ;;^UTILITY(U,$J,358.3,16364,0)
 ;;=N18.1^^88^876^15
 ;;^UTILITY(U,$J,358.3,16364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16364,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,16364,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,16364,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,16365,0)
 ;;=N18.2^^88^876^16
 ;;^UTILITY(U,$J,358.3,16365,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16365,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 2
 ;;^UTILITY(U,$J,358.3,16365,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,16365,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,16366,0)
 ;;=N18.3^^88^876^17
 ;;^UTILITY(U,$J,358.3,16366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16366,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 3
 ;;^UTILITY(U,$J,358.3,16366,1,4,0)
 ;;=4^N18.3
 ;;^UTILITY(U,$J,358.3,16366,2)
 ;;=^5015604
 ;;^UTILITY(U,$J,358.3,16367,0)
 ;;=N18.4^^88^876^18
 ;;^UTILITY(U,$J,358.3,16367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16367,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 4
 ;;^UTILITY(U,$J,358.3,16367,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,16367,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,16368,0)
 ;;=N18.5^^88^876^19
 ;;^UTILITY(U,$J,358.3,16368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16368,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,16368,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,16368,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,16369,0)
 ;;=Q61.3^^88^876^87
 ;;^UTILITY(U,$J,358.3,16369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16369,1,3,0)
 ;;=3^Polycystic Kidney,Unspec
 ;;^UTILITY(U,$J,358.3,16369,1,4,0)
 ;;=4^Q61.3
 ;;^UTILITY(U,$J,358.3,16369,2)
 ;;=^5018797
 ;;^UTILITY(U,$J,358.3,16370,0)
 ;;=N20.1^^88^876^11
 ;;^UTILITY(U,$J,358.3,16370,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16370,1,3,0)
 ;;=3^Calculus Ureter
 ;;^UTILITY(U,$J,358.3,16370,1,4,0)
 ;;=4^N20.1
 ;;^UTILITY(U,$J,358.3,16370,2)
 ;;=^5015608
 ;;^UTILITY(U,$J,358.3,16371,0)
 ;;=N18.9^^88^876^20
 ;;^UTILITY(U,$J,358.3,16371,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16371,1,3,0)
 ;;=3^Chronic Kidney Failure,Unspec
 ;;^UTILITY(U,$J,358.3,16371,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,16371,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,16372,0)
 ;;=N18.6^^88^876^30
 ;;^UTILITY(U,$J,358.3,16372,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16372,1,3,0)
 ;;=3^End Stage Renal Disease (ESRD)
 ;;^UTILITY(U,$J,358.3,16372,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,16372,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,16373,0)
 ;;=N52.9^^88^876^47
 ;;^UTILITY(U,$J,358.3,16373,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16373,1,3,0)
 ;;=3^Erectile Dysfunction,Unspec
 ;;^UTILITY(U,$J,358.3,16373,1,4,0)
 ;;=4^N52.9
 ;;^UTILITY(U,$J,358.3,16373,2)
 ;;=^5015763
 ;;^UTILITY(U,$J,358.3,16374,0)
 ;;=N32.81^^88^876^82
 ;;^UTILITY(U,$J,358.3,16374,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16374,1,3,0)
 ;;=3^Overactive Bladder
 ;;^UTILITY(U,$J,358.3,16374,1,4,0)
 ;;=4^N32.81
 ;;^UTILITY(U,$J,358.3,16374,2)
 ;;=^5015652
 ;;^UTILITY(U,$J,358.3,16375,0)
 ;;=Q61.2^^88^876^86
